Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of teroydeo kanser.
Sinabi ni Eisai na ang Lenvima ay magiging bagong pamantayan para sa klinikal na paggamot ng hindi nareresect na thyroid cancer. Ang industriya ay napaka-optimistiko tungkol sa Lenvima, at inaasahan na ang gamot ay magiging isang bagong cash cow para sa Eisai, na may taunang benta na tumataas sa higit sa $ 1 bilyon.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved pamamaga volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Sa kasalukuyan, kahit na ang karamihan sa mga uri ng thyroid cancer ay maaaring gamutin, may ilang mga opsyon para sa paggamot kapag lumala ito. Ang differential thyroid cancer (DTC) ay ang pinakakaraniwang malignant na thyroid tumor, at ang insidente nito ay patuloy na tumaas sa mga nakaraang taon.
Ang Lenvatinib ay isang oral multi-receptor tyrosine kinase (RTK) inhibitor na may novel binding mode. Bilang karagdagan sa pag-iwas sa iba pang mga RTK na kasangkot sa paglaganap ng tumor at oncogenic signaling pathways, maaari din nitong piliing pigilan ang aktibidad ng receptor kinase ng vascular endothelial growth factor (VEGF).
